002030 Stock Overview
Researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Daan Gene Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.42 |
| 52 Week High | CN¥11.00 |
| 52 Week Low | CN¥4.71 |
| Beta | 0.58 |
| 11 Month Change | 24.90% |
| 3 Month Change | 27.38% |
| 1 Year Change | -34.29% |
| 33 Year Change | -65.22% |
| 5 Year Change | -0.97% |
| Change since IPO | -52.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002030 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 9.9% | 21.1% | 15.5% |
| 1Y | -34.3% | -7.6% | 1.2% |
Return vs Industry: 002030 underperformed the CN Biotechs industry which returned -7.6% over the past year.
Return vs Market: 002030 underperformed the CN Market which returned 1.2% over the past year.
Price Volatility
| 002030 volatility | |
|---|---|
| 002030 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in CN Market | 9.4% |
| 10% least volatile stocks in CN Market | 4.5% |
Stable Share Price: 002030's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 002030's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,968 | Luo Huang | www.daangene.com |
Daan Gene Co., Ltd. researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables. The company offers fluorescence quantitative PCR products, enzyme-linked immunoassay products, instrument products, and scientific research service products. It also provides medical examination, and health consultation and management services, such as genetic susceptibility gene testing, tumor marker testing, cervical cancer screening, routine physical examination, and other health services.
Daan Gene Co., Ltd. Fundamentals Summary
| 002030 fundamental statistics | |
|---|---|
| Market cap | CN¥9.01b |
| Earnings (TTM) | -CN¥697.31m |
| Revenue (TTM) | CN¥1.05b |
8.6x
P/S Ratio-12.9x
P/E RatioIs 002030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002030 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.05b |
| Cost of Revenue | CN¥770.68m |
| Gross Profit | CN¥274.38m |
| Other Expenses | CN¥971.69m |
| Earnings | -CN¥697.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 26.25% |
| Net Profit Margin | -66.72% |
| Debt/Equity Ratio | 1.3% |
How did 002030 perform over the long term?
See historical performance and comparison